Cargando…
Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Purpose: The role of targeted therapy in the neoadjuvant field of stage IIIA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is still controversial. We sought to evaluate the efficacy and safety of neoadjuvant targeted therapy (NTT) with neoadjuvant chemo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417411/ https://www.ncbi.nlm.nih.gov/pubmed/34490338 http://dx.doi.org/10.3389/fsurg.2021.715318 |
_version_ | 1783748375389143040 |
---|---|
author | Chen, Dong Jin, Zixian Zhang, Jian Xu, Congcong Zhu, Kanghao Ruan, Yuhang Zhang, Bo Chen, Baofu Shen, Jianfei |
author_facet | Chen, Dong Jin, Zixian Zhang, Jian Xu, Congcong Zhu, Kanghao Ruan, Yuhang Zhang, Bo Chen, Baofu Shen, Jianfei |
author_sort | Chen, Dong |
collection | PubMed |
description | Purpose: The role of targeted therapy in the neoadjuvant field of stage IIIA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is still controversial. We sought to evaluate the efficacy and safety of neoadjuvant targeted therapy (NTT) with neoadjuvant chemotherapy (NCT) used as a benchmark comparator. Methods: A systematic search was conducted in four databases (Pubmed, Cochrane Library, Embase, CNKI) for eligible studies on NTT published before October 2020. The primary endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and grade 3/4 adverse events (AEs). Statistical analysis and bias assessment were performed by RevMan 5.3. Results: A total of 319 patients, including 3 randomized controlled trials and 2 non-randomized controlled trials, were included in the meta-analysis. Perform the second subgroup analysis after excluding 2 non-randomized controlled trials. The meta-analysis reveals that, for EGFR mutation-positive stage IIIA NSCLC patients, compared with NCT, NTT can significantly increase ORR (relative risk [RR]:1.70, 95% confidence interval [CI]:1.35–2.15; subgroup-RR:1.56, 95% CI 1.23–2.0) and significantly reduce grade 3/4 AEs (RR:0.5, 95% CI 0.34–0.75; subgroup-RR: 0.53, 95% CI 0.26–1.08). The OS of the NTT arm is slightly higher, but the difference is not significant (hazards ratio [HR]: 0.74, 95% CI: 0.43–1.27; subgroup-HR: 0.64 95% CI 0.40–1.03). No difference in PFS was found (HR: 0.81, 95% CI 0.27–2.44). Conclusion: In neoadjuvant setting, targeted therapy has a definitive effect on patients with EGFR mutation-positive stage IIIA NSCLC and is even better than chemotherapy in terms of toxicity and tumor response rate. Systematic Review Registration: PROSPERO, identifier CRD42021221136. |
format | Online Article Text |
id | pubmed-8417411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84174112021-09-05 Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis Chen, Dong Jin, Zixian Zhang, Jian Xu, Congcong Zhu, Kanghao Ruan, Yuhang Zhang, Bo Chen, Baofu Shen, Jianfei Front Surg Surgery Purpose: The role of targeted therapy in the neoadjuvant field of stage IIIA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is still controversial. We sought to evaluate the efficacy and safety of neoadjuvant targeted therapy (NTT) with neoadjuvant chemotherapy (NCT) used as a benchmark comparator. Methods: A systematic search was conducted in four databases (Pubmed, Cochrane Library, Embase, CNKI) for eligible studies on NTT published before October 2020. The primary endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and grade 3/4 adverse events (AEs). Statistical analysis and bias assessment were performed by RevMan 5.3. Results: A total of 319 patients, including 3 randomized controlled trials and 2 non-randomized controlled trials, were included in the meta-analysis. Perform the second subgroup analysis after excluding 2 non-randomized controlled trials. The meta-analysis reveals that, for EGFR mutation-positive stage IIIA NSCLC patients, compared with NCT, NTT can significantly increase ORR (relative risk [RR]:1.70, 95% confidence interval [CI]:1.35–2.15; subgroup-RR:1.56, 95% CI 1.23–2.0) and significantly reduce grade 3/4 AEs (RR:0.5, 95% CI 0.34–0.75; subgroup-RR: 0.53, 95% CI 0.26–1.08). The OS of the NTT arm is slightly higher, but the difference is not significant (hazards ratio [HR]: 0.74, 95% CI: 0.43–1.27; subgroup-HR: 0.64 95% CI 0.40–1.03). No difference in PFS was found (HR: 0.81, 95% CI 0.27–2.44). Conclusion: In neoadjuvant setting, targeted therapy has a definitive effect on patients with EGFR mutation-positive stage IIIA NSCLC and is even better than chemotherapy in terms of toxicity and tumor response rate. Systematic Review Registration: PROSPERO, identifier CRD42021221136. Frontiers Media S.A. 2021-08-19 /pmc/articles/PMC8417411/ /pubmed/34490338 http://dx.doi.org/10.3389/fsurg.2021.715318 Text en Copyright © 2021 Chen, Jin, Zhang, Xu, Zhu, Ruan, Zhang, Chen and Shen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Surgery Chen, Dong Jin, Zixian Zhang, Jian Xu, Congcong Zhu, Kanghao Ruan, Yuhang Zhang, Bo Chen, Baofu Shen, Jianfei Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title | Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_full | Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_fullStr | Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_short | Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis |
title_sort | efficacy and safety of neoadjuvant targeted therapy vs. neoadjuvant chemotherapy for stage iiia egfr-mutant non-small cell lung cancer: a systematic review and meta-analysis |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417411/ https://www.ncbi.nlm.nih.gov/pubmed/34490338 http://dx.doi.org/10.3389/fsurg.2021.715318 |
work_keys_str_mv | AT chendong efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT jinzixian efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhangjian efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT xucongcong efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhukanghao efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT ruanyuhang efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT zhangbo efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT chenbaofu efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis AT shenjianfei efficacyandsafetyofneoadjuvanttargetedtherapyvsneoadjuvantchemotherapyforstageiiiaegfrmutantnonsmallcelllungcancerasystematicreviewandmetaanalysis |